Diabetes: Prescribing of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2 inhibitors) and risk of Diabetic Ketoacidosis (including in patients with COVID-19) (APC Approved) prescribing guideline
- Summary
- Clinical support by body system
- Conditions and indicators
- Due for review01 September 2025
- Traffic light
- Link
- Bypass detail pageNo
- Bypass detail page and
- Clinical Support Group
Do you want to add this to your CPD record?
Did you find this page helpful?